Bovine leukemia virus (BLV) from either persistently infected bat cells or fetal lamb kidney cells induced rapid syncytium formation in F81 indicator cells. Distinct syncytia were seen within 2 h after inoculation of cells with highly concentrated (500-fold) cell-free BLV preparations and within 4 to 8 h when unconcentrated cell-free BLV preparations were used. Indicator cell densities of 1 x 105 to 2 x 105 were optimal for rapid and maximal syncytium formation.
1 x 105 to 2 x 105 were optimal for rapid and maximal syncytium formation.
Pretreatment of BLV with reference BLV leukemic serum and antiserum prepared against purified BLV significantly inhibited (95%) syncytium formation. Reference bovine viral diarrhea virus serum, foamy-like bovine syncytial virus serum, and control serum had little effect (17% inhibition). Antiserum to BLV gp51 inhibited syncytium formation by greater than 96%, whereas antiserum to BLV p24 reduced syncytium activity to a much lesser extent (38% inhibition). Treatment of BLV with fB-propiolactone (0.005 to 0.05%) had little or no effect upon syncytium-forming activity, whereas UV irradiation (15 ergs/mm2 per s for 30 min) reduced, but did not completely destroy, the fusion activity. However, both 83-propiolactone and UV irradiation drastically reduced the replication potential of BLV, as demonstrated by the lack of p24 expression in the inoculated cells. Concentrations of cycloheximide, cytosine arabinoside, tunicamycin, and 2-deoxy-D-glucose which effectively blocked cellular macromolecular synthesis did not significantly inhibit syncytium formation. These latter results suggested that de novo protein and DNA synthesis as well as protein glycosylation were not required for early syncytium formation. Thus, these experiments demonstrated that replication of BLV by the indicator cells was not essential for cell fusion.
It has been demonstrated that bovine leukemia virus (BLV) can induce cell fusion in several nontransformed indicator cells, such as human embryonic diploid lung, bovine embryonic spleen, and bat lung cells (6) , as well as in sarcoma virus-transformed F81 cells (1). Distinct syncytia were seen in nontransformed cells at 4 to 8 days post-inoculation (6) and 16 days after inoculation of the F81 cells (1), suggesting that infection of the indicator cells and replication of BLV in these cells were necessary for syncytium induction. This phenomenon is often referred to as "late" polykaryocytosis or "fusion from within," in contrast to "early" polykaryocytosis or "fusion from without" in which syncytium induction can be seen within a few hours postinoculation (19) . Early polykaryocytosis has been demonstrated with mixed cultures of BLVproducing cells and sarcoma-transformed KC, XC, and CC81 (15, 18) cells. Maximum amounts of syncytia were seen as soon as 24 h after initiation of the mixed cultures. Before the results presented in this paper, induction of early polykaryocytosis by cell-free BLV had not been reported.
The major objective of this study was to gain a better understanding of the mechanism of syncytium induction by determining whether or not cell-free BLV in the absence of BLV-producing cells could induce early syncytia. To do this, we tested concentrated and unconcentrated cell-free preparations of BLV for the ability to induce syncytia in F81 cells early after inoculation. In addition, the effects of various metabolic inhibitors as well as f8-propiolactone (BPL) and UV treatment of BLV were tested on BLV-induced syncytium formation in the F81 indicator cells. If one assumes that early polykaryocytosis is due to a structural component of intact BLV and that infection of the indicator cells is not necessary, metabolic inhibitors, such as cycloheximide, l-fB-D-arabinofuranosylcytosine (ara-C), and tunicamycin, should have no effect upon polykaryocyte formation. In addition, destruction of the infectivity of BLV with BPL and UV irradiation should have little or no effect. (12) , and fetal lamb kidney (FLK) cells, designated BLV-FLK (24), were used as the sources of BLV throughout this study. Since BLV preparations from both sources gave similar results in all the experiments presented, the term "BLV preparation" used herein refers to either source unless specified otherwise. The origin and properties of the BLV-bat2 and BLV-FLK cells have been reported previously (12, 24) . The BLV-FLK cells and the F81 feline cell line (8) , which contains the murine sarcoma virus genome and was used as indicator for the syncytium assays, were kindly supplied by M. J. Van der Maaten. All cell lines were grown at 37°C in Eagle minimal essential medium supplemented with 10% heat-inactivated fetal calf serum, 100 U of penicillin, and 100 jig of streptomycin sulfate per ml (MEM). They were routinely subcultured every 4 to 5 days by dispersion with 0.05% trypsin and 0.06% EDTA and reseeded into 150-cm2 flasks at a concentration of 106 cells per flask. All cells were tested for mycoplasma and found negative.
Cell-free preparations of BLV were obtained by low-speed centrifugation (10,000 x g for 10 min) of culture fluids from infected cell lines 72 to 96 h after subculturing, followed by filtration through a 0.45-jim Nalgene filter. Concentrated (500-fold) BLV prepartions were prepared initially by concentrating 2,000 ml of cell-free culture fluid to 200 ml with an Amicon concentrator (DC2, hollow fiber HlP100). BLV was pelleted from the concentrated culture fluid by ultracentrifugation (110,000 x g for 60 min) and then resuspended in 4 ml of MEM, giving a final 500-foldconcentrated preparation of BLV.
Sera. The bovine sera used in this study were serum 1001, from a normal control animal; serum 4000, from a confirmed case of lymphosarcoma; 3892, from an animal negative for BLV antibodies but positive for antibodies to the widespread foamy-like bovine syncytial virus (BSV); and serum 7767, from an animal positive for antibodies to bovine viral diarrhea virus (BVDV) but negative for antibodies to BLV. Serum 4000 had antibodies to the internal and envelope antigens of BLV but was negative for antibodies to the BSV. These sera were kindly supplied by M. J. Van der Maaten and C. Olson. Antisera to the major internal protein (p24) and the major envelope glycoprotein (gp5l) were prepared in rabbits and obtained from A. Burny (11) UV irradiation of BLV. Samples (0.5 ml) of cellfree BLV preparations (concentrated and unconcentrated) were placed into serile plastic petri dishes and exposed to UV light (Mineralight; Ultra-Violet Products, Inc., South Pasadena, Calif.) for 10, 20, and 30 min at an incident dose rate of 15 ergs/mm2 per s. The irradiated BLV preparations and an unirradiated preparation of BLV were then tested on F81 cells for syncytium-forming ability as described above.
BPL treatment. Cell-free preparations of concentrated and unconcentrated BLV were incubated overnight at 4°C with concentrations of BPL ranging from 0.005 to 0.05%, using a method similar to that described by Wainberg et al. (25) for inactivating Sendai virus. Briefly, a freshly prepared 10% solution of BPL was diluted in serum-free MEM to 10 times the desired final BPL concentration. One milliliter of this 10-foldconcentrated BPL solution was then added to 9 ml of cell-free BLV preparation, and the mixture was shaken at 4°C for 10 min and placed onto a shaker in a 37°C incubator and shaken for another 2 h. As a control, a BLV preparation was handled in an identical manner, but without BPL treatment. After overnight incubation of the mixtures at 4°C, they were tested for syncytium-inducing ability as described above.
Immunofluoresence. Our indirect immuno-EARLY SYNCYTIUM FORMATION BY BLV 1057 fluoresence procedure was a modification of that used by Diglio and Ferrer (6) . In brief, inoculated and uninoculated F81 cells were treated with trypsin-EDTA, washed once with phosphate-buffered saline, and adjusted to a concentration of 5 x 105 cells per ml, and 0.05 ml was placed onto a glass slide, air dried, and then fixed with acetone for 10 min. Fixed cells were then incubated with rabbit anti-p24 antiserum (diluted 1:10 in phosphate-buffered saline) for 30 mi at 37°C. After this incubation, the cells were washed in phosphate-buffered saline, and fluorescein-conjugated goat anti-rabbit immunoglobulin G diluted 1:10 in phosphate-buffered saline was added. After incubation for a further 30 min at 37°C, the cells were washed with phosphate-buffered saline, a drop of glycerin diluted 1:1 in phosphate-buffered saline was placed on the cells, and the cells were covered with a glass cover slip and immediately examined with a Leitz fluorescence microscope. (ii) Treatment with metabolic inhibitors. Each of four wells of the F81 indicator cells was treated with 0.25 ml of cycloheximide (10 ,ug/ml), ara-C (10 Ag/mil), tunicamycin (5 ,ug/ml), or 2-deoxy-D-glucose (1.64 mg/ ml) at -60 min (1 h before virus inoculation) and at zero time (the time at which cells were inoculated with virus). Two of the four wells of cells treated with inhibitors at -60 min and at zero time were inoculated with 0.25 ml of a concentrated virus preparation, which remained on the cells along with the inhibitors throughout the experiment (8 h). These cells, along with duplicate wells of cells inoculated with virus only, were stained in order to determine syncytium formation. To the remaining one-half of the cells that were treated with inhibitors, radioactive precursors were added as described below. In addition, duplicate wells of F81 cells were treated with radioactive precursors only in order to determine the extent of inhibition of macromolecular synthesis.
( 
RESULTS
Kinetics of syncytium formation with unconcentrated and concentrated BLV preparations. In our initial studies, inoculation of DEAE-dextran-treated F81 cells with either an unconcentrated or a concentrated (500-fold) BLV preparation from either BLV-bat2 or BLV-FLK cells resulted in syncytium formation. Discrete syncytia were seen by 4 to 8 h post-inoculation, earlier than had been reported previously for cell-free preparations of BLV (1, 7, 15) . To determine the rate of syncytium formation, F81 cells were seeded into multiwell culture plates and treated with DEAE-dextran as described in Materials and Methods and then inoculated with unconcentrated or concentrated BLV preparations. The temporal progression of syncytium formation was followed by staining duplicate samples at 2-h intervals for 24 h. Results from these experiments are shown in Fig.  1 . When concentrated BLV preparations were used, the majority of the cells were involved in cell fusion by 2 h post-inoculation and developed into large, discrete syncytia within 24 h. Using unconcentrated cell-free preparations of BLV, fused cells containing two to four nuclei were relatively abundant within 2 h after inoculation (results not shown). The number and size of syncytia increased rapidly with time, and by 4 h a majority of the syncytia contained between five and eight nuclei (Fig. 1) Specificity of cell fusion activity by BLV.
To confirm that BLV, and not some other adventitious agent, was responsible for syncytium formation, inhibition studies with well-defined reference and control sera were conducted. control serum 1001, which was negative for antibodies to BLV, BVDV, and BSV, had no significant effect (13% inhibition) (Table 1) . Reference sera 7826 and 3892, which had high titers of antibodies to BVDV and BSV, respectively, did not significantly inhibit syncytium formation (17 and 15% respectively). Sera prepared against purified BLV that had been disrupted by freezing and thawing four times inhibited (95%) syncytium formation quite effectively. These results implied that the syncytium formation in F81 cells by cell-free preparations from BLV-FLK cells was due to BLV, and not BVDV or BSV. Also included in Table  1 are data showing that rabbit antiserum to the major glycoprotein, gp5l, showed significant inhibition (96%) of syncytium formation, whereas rabbit antiserum to the major internal protein, p24, inhibited syncytium formation to a much lesser extent (38%). These data suggest that gp5l, an external component of BLV, may play a major role in syncytium induction. Experiments with cell-free preparations of BLV from BLV-bat2 cells were conducted, and similar results were obtained (data not shown).
Effects of BPL and UV irradiation on the cell fusion activity of BLV. To further demonstrate that BLV could induce early syncytia, or cell fusion from without, unconcentrated and concentrated preparations of BLV were treated with various concentrations of BPL or exposed expression was not taking place in these cells. Cells inoculated with BLV that had been exposed to UV irradiation (15 ergs/mm2 per s) for 20 and 30 min also showed no viral antigen expression at any of the time periods tested. However, cells that were inoculated with BLV that had been exposed to UV irradiation for only 10 min showed weak cytoplasmic fluorescence at 24 h, suggesting that 10-min exposure to UV irradiation was probably not sufficient to destroy all the replicating potential of BLV. No fluorescence was seen in cells inoculated with unconcentrated preparations of BLV that had been treated with either BPL or UV irradiation. Bright fluorescence in both individual and fused cells was seen at 8 and 24 h in F81 cells that had been inoculated with untreated concentrated and unconcentrated BLV preparations, respectively.
Thus, these results suggested that cell fusion and virus replication (expression of BLV p24) were independent events, since BPL treatment and UV irradiation of BLV resulted in a loss of BLV antigen expression, but not a loss of induction of cell fusion.
Effects of metabolic inhibitors on the fusion of F81 cells by BLV. The ability of BLV to induce early syncytium formation in F81 indicator cells was demonstrated. However, to further elucidate the requirements necessary for BLV-induced early cell fusion, experiments were set up with various inhibitors of macromolecular synthesis. F81 cells were treated with ara-C (10 Ag/ml), cycloheximide (10 ,ug/ml), tunicamycin (5 ,ug/ml), 2-deoxy-D-glucose (1.64 mg/ml), or no inhibitor for 1 h before inoculation or at the same time that cells were inoculated with BLV and remained on the cells throughout the 8 h of incubation (Table 4) . Cycloheximide and ara-C had little or no effect upon syncytium formation by BLV (Table 4) . ara-C, an inhibitor of DNA synthesis which has been shown to block the replication of retroviruses by inhibiting the synthesis of proviral DNA (4, 22) , significantly inhibited (96% inhibition) cellular DNA synthesis, but inhibited syncytium formation by less than 5%. Furthermore, cycloheximide at a concentration of 10 ,ug/ml had a drastic effect upon protein synthesis (93% inhibition), but no significant inhibition was observed in syncytium formation (<5%). Thus, early cell fusion by BLV did not appear to require de novo protein or DNA synthesis, which can be inhibited by cycloheximide or ara-C (Table 4 ). Recognizing the fact that specific glycoprotein synthesis or protein glycosylation may have played a role in cell fusion, as has been demonstrated for other systems (10, 21) , two inhibitors of protein glycosylation were included in the metabolic inhibitor experiments (Table 4) . Both tunicamycin and 2-deoxy-D-glucose reduced glycoprotein synthesis by greater than 68 and 80%, respectively, but had only marginal effects on syncytium fornation. These 
DISCUSSION
The results from our studies demonstrate that concentrated cell-free preparations of BLV can induce early syncytium formation in F81 cells. Such rapid virus-induced cell fusion is considered fusion from without, in contrast to fusion from within (19) . This conclusion is suggested by: (i) the very rapid appearance of syncytia, within 2 to 4 h after inoculation of F81 cells; (ii) the ability of BPL-treated and UV-irradiated BLV preparations to retain cell-fusing activity; and (iii) the lack of a requirement for protein and DNA synthesis as well as protein glycosylation for syncytium formation to occur. Thus, it seems that the replication of BLV is not essential for cell fusion and that the phenomenon may be considered fusion from without.
The specificity of the cell fusion induced by cell-free preparations of BLV-bat lung and BLV-FLK cell cultures was studied thoroughly. Culture fluids from normal bat2 cells and FLK cells were assayed for syncytium-inducing ability and found negative. (7) and Irgens et al. (15) used CC-81 cells, which could be the reason why these researchers did not obtain early syncytium formation with cell-free preparations of BLV. This assumption is further strengthened by the fact that Jerabek et. al. (16) noticed that the CC-81 cell cultures contained few cells that were susceptible to BLV infection and thus were capable of becoming syncytiuminducing (effector) cells. Assuming that CC-81 and F81 cells were originally identical, as established by Fischinger et al. (8, 9) , the reason for the variation in syncytium-inducing ability is unknown. It (4, 14, 23, 26, 27) .
Preparations of BLV that were UV irradiated (15 ergs/mM2 per s) for 20 to 30 min were found to possess significant fusion activity (>19% of the fusion activity of non-UV-irradiated BLV) for F81 cells. These results imply that a functional viral genome is not required for early syncytium formation. Thus, assuming that BLV induces fusion from without, the question arises of why UV irradiation of unconcentrated BLV reduced cell fusion activity by 70 to 80% as compared with non-UV-irradiated BLV. One possible explanation is that UV irradiation had denaturing effects upon some component of BLV, perhaps a protein, necessary for cell fusion (2) . More convincing evidence showing that noninfectious and nonreplicating BLV is capable of inducing early syncytia was presented by using metabolic inhibitors. These studies conclusively illustrated that concentrations of cycloheximide (10 jig/ml), ara-C (10 ,ug/ml), tunicamycin (5 ,ugl ml), and 2-deoxy-D-glucose (1.64 mg/ml) that significantly inhibited cellular macromolecular synthesis had little or no effect upon BLV-induced cell fusion. These results further support the hypothesis that BLV can induce fusion from without.
The exact nature of the factor or factors responsible for BLV-induced cell fusion in F81 cells is unknown. However, (i) the ability of UVirradiated and BPL-treated BLV to induce syncytia in F81 cells and (ii) the fact that metabolic inhibitors had little or no effect upon syncytium formation are consistent with the hypothesis that early BLV-induced fusion activity may be associated with a BLV virion component(s). Furthermore, since antiserum prepared against purified BLV particles and against the major glycoprotein of BLV neutralize the syncytiumforming ability of BLV, it is likely that external proteins, possibly the viral spikes, play a major role in cell fusion, as in the case of other lipoprotein-enveloped viruses (3, 20, 27) .
In conclusion, the results presented in this paper clearly demonstrate that cell-free preparations of BLV can induce early syncytium formation in F81 cells, a phenomenon referred to as fusion from without (19) . On the other hand, several investigators (1, 6) have reported that BLV induces syncytia by a mechanism that requires infectious virus and corresponds to a phenomenon known as late polykaryocytosis, or fusion from within. It seems feasible, therefore, that BLV, like other enveloped viruses (3, 17, 27) , can induce cell fusion by both mechanisms.
